Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral pIL-12 Electroporation in TNBC
NCT02531425Phase 1Completed
- Sponsor
- OncoSec Medical
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tavokinogene telseplasmid in triple-negative breast cancer (TNBC), sponsored by OncoSec Medical. Primary endpoints: Changes in the proportion of intratumoral lymphocyte subsets at 28 days and NanoString-based gene expression at 28 days. Started Sep 2015; status: completed.
02
Drugs
tavokinogene telseplasmid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02531425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531425.